Docket #: S10-397
Scaffold-kinase interaction blockade for treatment of RAS/MAPK-Pathway driven cancers
Researchers in Prof. Paul Khavari's laboratory have discovered a novel compound and method to block invasive neoplasia without effects on normal cells. This technology targets a small domain (WW domain) of a scaffolding protein (IQGAP1) that binds proteins in the Ras/MAP kinase-signaling pathway. The Ras-Raf-Mek-Erk MAPK pathway is implicated in >40% of all human cancers, but targeting components of the pathway have not yielded valid therapeutics due to the risk of side effects on normal cells and mechanisms of acquired resistance. Targeting scaffold proteins rather than the canonical kinases provides a unique approach to develop therapies to treat a range of solid tumors without affecting homeostasis of normal tissues as well as to circumvent acquired tumor resistance to kinase inhibitors.
Applications
- Cancer therapeutic — to prevent and/or diminish tumor formation, proliferation, and/or metastasis in >40% of all human cancers characterized as Ras-Raf-Mek-Erk MAPK pathway overexpressing.
Advantages
- Tumor-selective — this domain is NOT required for normal human tissue homeostasis, therefore it could affect tumorigenesis without side effects on normal cells.
- Non-toxic — we have not observe any morbidity in WW-treated mice nor did we find anysignificant hematological or chemical abnormalities.
Publications
- Jameson KL, Mazur PK, Zehnder AM, Zhang J, Zarnegar B, Sage J, Khavari PA. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nature Medicine. 2013 Apr 21.
- Patent application PCT/US2012/032375: Scaffold-Kinase Interaction Blockades and Uses Thereof in Treating Cancer
Stage of Research
General
A 30 amino acid peptide (WW) corresponding to a conserved scaffold domain disrupted neoplastic action of the Ras/MAPK pathway and significantly impairs proliferation of cancer cells in both in vitro and in vivo models as well as inhibits neoplastic invasion in a human tissue model of skin cancer.
Pancreatic Cancer
Genetically engineered mouse models expressing p48CRE, KRasG12D, p53fl/fl mutant mice rapidly develop advanced pancreatic lesions at 35 days of age characterized by both significant tumor burden and palpable tumor mass. Animals treated with gemcitabine, a chemotherapeutic agent commonly used in pancreatic ductal adenocarcinoma patients, had an average lifespan of 58 days. Data for systemic WW peptide treatment in mouse models of pancreatic cancer are available under confidentiality.
PLX-4032 Resistant Melanoma Skin Cancer
The newly available kinase inhibitor Vemurafenib (PLX-4032) targets mutant BRAFV600EMAP3K in melanoma, however, its long-term effectiveness has been hindered by acquired resistance via bypass mechanisms that restore Erk1/2 activation. Three PLX-4032sensitive BRAFV600E–expressing parental human melanoma cancer cell lines (COLO-829, SK-Mel-28, and A375) were rendered resistant to PLX-4032. PLX-4032 resistance of these resulting subclones was confirmed by assays of PLX-4032-mediated growth inhibition as compared to vehicle control (DMSO) and was accompaniedby genetic alterations previously associated with the emergence of PLX-4032 resistance including inIGF1-R, PDGFR-?, NRAS, and COT. Data for WW peptide treatment in models of PLX-4032 resistant melanoma skin cancer are available under confidentiality.
Related Links
Patents
- Published Application: 20140162960
- Issued: 9,155,774 (USA)
Similar Technologies
-
Novel systems for inhibiting Neuromedin signaling in vivo S15-356Novel systems for inhibiting Neuromedin signaling in vivo
-
Method to direct T-cell fate towards T stem cell memory phenotype S17-182Method to direct T-cell fate towards T stem cell memory phenotype
-
BMP Activators for Treating Bladder Cancer and Other Tumors S13-498BMP Activators for Treating Bladder Cancer and Other Tumors